Targeted Complex Therapy for Advanced Melanoma and Gynecologic Cancers: Nab-Paclitaxel (Abraxane)/Bevacizumab Complex (AB-Complex)
Phase of Trial: Phase I
Latest Information Update: 07 Aug 2019
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Carcinoma; Cervical cancer; Endometrial cancer; Fallopian tube cancer; Malignant melanoma; Ovarian cancer; Peritoneal cancer; Sarcoma; Squamous cell cancer
- Focus Adverse reactions
- 02 Aug 2019 Planned primary completion date changed from 1 Jun 2025 to 3 Feb 2020.
- 25 Jun 2019 Status changed from suspended to recruiting.
- 20 May 2019 Status changed from recruiting to suspended.